🔎 Trials Near Me

Home › Insomnia › NCT05814822

Targeting Insomnia to Improve Outcomes in Adults With Problematic Cannabis Use

Recruiting

Who can join

Ages 21 and older · All sexes

Full eligibility criteria
INCLUSION CRITERIA

* 21 years of age and older, the age needed to obtain full legal access to cannabis in Michigan
* Self-reported chronic insomnia (nighttime symptoms of difficulty initiating and/or maintaining sleep and/or early morning awakenings on ≥3 nights for ≥3 months with daytime impairment), consistent with DSM-5 diagnosis of Insomnia Disorder
* Insomnia Severity Index (ISI) score ≥11, indicative of at least "mild" insomnia
* A positive urine drug screen (UDS) for cannabis33
* Self-reported use of cannabis at least three times weekly for the past month
* Stable residence (e.g., stable sleep arrangements), consistent access to Wi-Fi, and ability to travel to Ann Arbor for sleep laboratory assessments

EXCLUSION CRITERIA

* Individuals who do not understand English (read and spoken)
* Individuals judged unable to provide informed consent (e.g., intoxication, mental incompetence)
* Diagnosis or high suspicion of a sleep disorder other than insomnia
* Lifetime diagnosis of psychotic disorder or bipolar disorder; current post-traumatic stress disorder that directly interferes with sleep
* Terminal or progressive physical illness (e.g., cancer) or neurological degenerative disease (e.g., dementia)
* Use of medications known to have initiated their insomnia (e.g., steroids)
* Previous receipt of CBTi
* Self-reported pregnancy
* Self-reported regular work schedule of rotating or night (3rd) shift work
* Other conditions and situations, medical or otherwise, that preclude meaningful and/or safe participation in CNT/SHE and study procedures

About the study

This study will compare the efficacy of telemedicine-delivered cognitive behavioral therapy for insomnia tailored for people using cannabis for sleep (CBTi-CB-TM) to telemedicine-delivered sleep hygiene education (SHE-TM) on sleep, cannabis use, and daytime functioning. We will also evaluate the effects of CBTi-CB-TM on fundamental sleep regulatory system - homeostatic sleep drive - and its association with clinical outcomes.

What is being tested

Sponsor: University of Michigan · Participants: 200 · Started: Jun 1, 2023

Contact the study team

Official record on ClinicalTrials.gov — NCT05814822

Locations in the U.S.

MichiganUniversity of Michigan, Ann Arbor

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.